Omalizumab

CAT#: TP-097CL

A recombinant DNA-derived humanized IgG1k monoclonal antibody that selectively binds to human immunoglobulin E (IgE). omalizumab is produced by a Chinese hamster ovary cell suspension culture in a nutrient medium containing the antibiotic gentamicin.

Gene Expression
Figure 1 Colon Figure 2 Liver Figure 3 Kidney Figure 4 Testis Figure 5 RNA cell line category: Group enriched (Karpas-707, U-698)

Specifications

  • Type
  • Biotech
  • Trade name
  • omalizumab
  • UNII
  • 2P471X1Z11

Target

  • Function
  • Humanized mAb that inhibits ige binding to the high-affinity ige receptor on mast cells and basophils, decreasing activation of these cells and release of inflammatory mediators
REVIEWS AND Q&AS CITATIONS RESOURCES DOWNLOADS RELATED PRODUCTS
Inquiry
Navs

Customer Review

Submit a review or a question

There are currently no Customer reviews or questions for TP-097CL. Click the button above to contact us or submit your feedback about this product.
Breast cancer biomarkers at key points during disease progression
Excellent for Allergy Studies
Omalizumab has revolutionized our allergy research methodologies. Its high specificity for IgE allowed us to closely examine immune responses without interference. The clarity it brought to our IgE receptor studies was unparalleled, making it a staple in our lab.
Breast cancer biomarkers at key points during disease progression
Exceptional Quality and Precision
The precision afforded by Omalizumab in blocking IgE was impressive. Its application in our bioassays resulted in reproducible data that furthered our exploration into immune modulating treatments.
Breast cancer biomarkers at key points during disease progression
Consistent and Dependable Results
With Omalizumab, we consistently obtained dependable results in our IgE-focused assays. Its specificity ensured minimized cross-reactivity, essential for accurate data interpretation.
Breast cancer biomarkers at key points during disease progression
Helps Map Signaling Pathways
It became a cornerstone in our studies mapping IgE signaling pathways. Omalizumab's use allowed us to chart detailed maps of allergic response mechanisms, offering insights into novel drug discovery.
Breast cancer biomarkers at key points during disease progression
Perfect for IgE Modulation Studies
Omalizumab's blocking action on IgE has been perfect for our studies on immune modulation. It helped reveal how IgE interactions affect broader immune responses, a critical aspect of our research.

Q&As

  1. What is the primary target of Omalizumab?

    A: Omalizumab targets human immunoglobulin E (IgE), a key player in allergic reactions. By binding to IgE, it prevents it from attaching to its receptors on immune cells, thereby dampening the allergic response.

  2. What are potential uses for Omalizumab in laboratory settings?

    A: This antibody can be utilized to investigate mechanisms of allergic inflammation, perform binding studies, and in bioassays to test the efficacy of novel therapies targeting IgE-related pathways.

  3. Can Omalizumab be used as a control in IgE-related assays?

    A: Yes, it can function as a control to evaluate the neutralization or binding capacity of other therapeutic candidates targeting IgE.

  4. How does Omalizumab help in studying immune cell interactions?

    A: By blocking IgE, it aids in dissecting the roles of mast cells and basophils in allergic and autoimmune responses, contributing to a better understanding of cell signaling and immune regulation.

  5. What is the role of Omalizumab in signaling pathway analysis?

    A: It serves as a critical tool in dissecting IgE-mediated signal transduction and understanding the broader implications of IgE receptor blockade on immune cell functions.

View the frequently asked questions answered by Creative Biolabs Support.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TP-097CL, RRID: AB_3112053)

Copy citation

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Article title:
DOI/PubMed URL:
Email:
Name:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Lot Number:

See other products for "IGHG1"

Select a product category from the dropdown menu below to view related products.

CAT Product Name Application Type
EPAF-0577CQ Mouse Anti-IGHG1 Recombinant Antibody (clone B3-18) ELISA Mouse IgM
CAT Product Name Application Type
VS-0425-YC67 Recombinant Anti-IGHG1 Vesicular Antibody, EV Displayed (VS-0425-YC67) ELISA, FC, Cell-uptake
CAT Product Name Application Type
VS-0525-XY3458 Anti-IGHG1 Immunohistochemistry Kit IHC
Specific Inquiry
Go to compare Add to compare

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Go to compare

Go to compare